Immunosuppressants - D-A-CH

D-A-CH

The Immunosuppressants market in D-A-CH is expected to witness a significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$1.65bn.
This growth is anticipated to continue with an annual growth rate of 15.73% from 2024 to 2028, ultimately resulting in a market volume of US$2.96bn by 2028.
In comparison to other countries, United States is expected to generate the highest revenue in the Immunosuppressants market, with an estimated revenue of US$33,610.00m in 2024.
In the D-A-CH region, Germany stands out as a leader in the market for immunosuppressants, with a strong emphasis on research and development.

Key regions: Italy, Canada, Australia, France, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in D-A-CH has been growing steadily in recent years.

Customer preferences: Patients suffering from autoimmune diseases or who have undergone organ transplants require immunosuppressants to prevent their immune systems from attacking their own bodies or the transplanted organ. The preference for these drugs is therefore driven by medical necessity rather than personal choice.

Trends in the market: The market for immunosuppressants in Germany, Austria, and Switzerland has been growing steadily due to the increasing prevalence of autoimmune diseases and organ transplant surgeries. In addition, the availability of newer and more effective drugs has also contributed to market growth. While generic drugs dominate the market, the demand for branded drugs is also increasing, especially among patients who require long-term treatment.

Local special circumstances: Germany is the largest market for immunosuppressants in D-A-CH, accounting for the majority of the market share. This is due to the high prevalence of autoimmune diseases and organ transplants in the country, as well as the availability of advanced healthcare facilities. Austria and Switzerland, on the other hand, have smaller markets due to their smaller populations and lower prevalence of autoimmune diseases.

Underlying macroeconomic factors: The healthcare sector in D-A-CH is well-developed and has a high level of public spending, which has contributed to the growth of the immunosuppressants market. In addition, the aging population in the region has also driven market growth, as the incidence of autoimmune diseases and organ transplants increases with age. The increasing availability of biosimilars is also expected to impact the market, as these drugs offer a cheaper alternative to branded immunosuppressants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.